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Abstract
Ocular neovascularization underlies major blinding eye diseases
such as “wet” age-related macular degeneration (AMD). Despite
the successes of treatments targeting the vascular endothelial
growth factor (VEGF) pathway, resistant and refractory patient
populations necessitate discovery of new therapeutic targets.
Using a forward chemical genetic approach, we identified the
heme synthesis enzyme ferrochelatase (FECH) as necessary for
angiogenesis in vitro and in vivo. FECH is overexpressed in wet
AMD eyes and murine choroidal neovascularization; siRNA knock-
down of Fech or partial loss of enzymatic function in the Fechm1Pas
mouse model reduces choroidal neovascularization. FECH depletion
modulates endothelial nitric oxide synthase function and VEGF
receptor 2 levels. FECH is inhibited by the oral antifungal drug
griseofulvin, and this compound ameliorates choroidal neovascu-
larization in mice when delivered intravitreally or orally. Thus,
FECH inhibition could be used therapeutically to block ocular
neovascularization.
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Introduction
Ocular neovascularization is a characteristic of blinding eye
diseases like retinopathy of prematurity, proliferative diabetic
retinopathy, and “wet” age-related macular degeneration (AMD;
Das & McGuire, 2003). These diseases cause vision loss through-
out life and together are the major cause of blindness in devel-
oped countries (Das & McGuire, 2003; Penn et al, 2008). All are
characterized by abnormal angiogenesis (neovascularization) in
the posterior segment of the eye (in the retina or choroid), lead-
ing to vascular leakage that can result in hemorrhage, edema,
and retinal detachment, with vision loss as a direct result. This
neovascularization is driven by a number of factors, prominent
among which is vascular endothelial growth factor (VEGF; Penn
et al, 2008).
Management of neovascular eye diseases has been revolution-
ized by the advent of anti-VEGF biologics such as ranibizumab,
bevacizumab, and aflibercept (Folk & Stone, 2010; Prasad et al,
2010; Hanout et al, 2013). However, despite these considerable
advances, treatment options remain limited for a substantial frac-
tion of patients who are non-responsive or refractory to anti-
VEGF therapy (Lux et al, 2007); no agents acting downstream of
the VEGF receptor interaction are yet approved for targeted ther-
apy of these diseases (Abouammoh & Sharma, 2011; Lally et al,
2012). There is thus a pressing need to identify alternative
targets in angiogenesis signaling that could form the basis for
new therapeutics. To uncover novel, potentially druggable angio-
genesis mediators, here we took a forward chemical genetic
approach to find protein targets of an antiangiogenic natural
product, cremastranone (Shim et al, 2004; Kim et al, 2007, 2008;
Lee et al, 2014; Basavarajappa et al, 2015). We identify ferroche-
latase (FECH) as a target of this compound and show that it is
necessary for angiogenesis in vitro and in vivo and targetable
with the FDA-approved small molecule drug, griseofulvin. FECH
is the terminal enzyme in heme biosynthesis, responsible for
catalyzing the insertion of Fe2+ ion into protoporphyrin IX
(PPIX; Hamza & Dailey, 2012). To our knowledge, we describe
here for the first time FECH’s role as a druggable mediator of
angiogenesis.
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Results
Ferrochelatase is a target of an antiangiogenic compound
To identify potentially novel protein modulators of angiogenesis, we
used photoaffinity chromatography to search for targets of the natu-
rally occurring antiangiogenic compound, cremastranone (Fig 1A),
which has selective antiproliferative effects on endothelial cells (Lee
et al, 2014). Protein binding partners of cremastranone were pulled
down from a tissue lysate using immobilized cremastranone-based
affinity reagent but not a negative control reagent (Fig 1B). One of
the two pulled-down proteins was identified using peptide mass fin-
gerprinting as FECH (Fig 1C and Appendix Fig S1). Immunoblot of
eluates from photoaffinity pull-down experiments confirmed the
identity of the pulled-down protein using an antibody against FECH
(Fig 1D). In order to confirm specificity of binding between cremas-
tranone and pulled-down proteins, the affinity reagent was incu-
bated with tissue proteins in the presence of excess active
cremastranone isomer (Fig 1B; Basavarajappa et al, 2014). Under
this condition, the binding of FECH to the affinity reagent was
markedly decreased (~87%), indicating competition for binding to
FECH between the cremastranone isomer and the affinity reagent
(Fig 1E).
Recombinant FECH also interacted with the affinity reagent
(Fig 1F and G), indicating that the interaction does not require
eukaryotic accessory proteins. Some binding to the negative control
is likely due to the abundance of recombinant protein present;
recent work confirms that cellular FECH does not readily bind link-
ers such as our control compound (Park et al, 2016). Moreover,
cremastranone treatment of human retinal endothelial cells (HRECs)
caused a dose-dependent buildup of the FECH substrate PPIX
(Fig EV1A), indicative of FECH inhibition, and addition of excess
5-aminolevulinic acid (5-ALA; the first precursor compound in the
heme biosynthetic pathway that promotes increased heme produc-
tion) partially rescued cremastranone’s antiproliferative effects on
HRECs (Fig EV1B). Cremastranone did not chelate iron, suggesting
that it does not act indirectly on FECH by sequestering FECH’s Fe2+
substrate (Fig EV1C). The FECH pathway, therefore, is targeted by a
known antiangiogenic compound, suggesting that this protein and
pathway are important for angiogenesis.
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Figure 1. Ferrochelatase (FECH) is a target of the antiangiogenic natural product, cremastranone.
A Chemical structure of cremastranone (1) (top). Antiproliferative activity of cremastranone (bottom) shown as the 50% growth inhibitory concentration (GI50) on
human retinal endothelial cells (HRECs), human umbilical vein endothelial cells (HUVECs), and non-endothelial ocular cells (uveal melanoma 92-1, retinoblastoma
Y-79, and retinal pigment epithelium ARPE-19).
B Structures of compounds used in photoaffinity chromatography.
C Proteins pulled down with indicated reagents (numbered as in B) in photoaffinity chromatography were separated on SDS–PAGE and silver-stained.
D Immunoblot of pulled-down proteins using antibody against ferrochelatase (FECH).
E Immunoblot of pulled-down proteins from competition assay with excess active cremastranone isomer (4); relative quantification of band intensity shown.
F Silver-stained SDS–PAGE gel of recombinant human FECH protein pulled down using photoaffinity chromatography.
G Anti-FECH immunoblot of recombinant human FECH protein pulled down using photoaffinity chromatography.
Data information: All the gel and immunoblot images are representative from at least two independent experiments.
Source data are available online for this figure.
EMBO Molecular Medicine ª 2017 The Authors
EMBO Molecular Medicine Ferrochelatase in neovascularization Halesha D Basavarajappa et al
2
Published online: April 4, 2017 
Ferrochelatase is required for angiogenesis in vitro
The role of FECH in angiogenesis has not previously been explored,
despite strong evidence linking heme catabolism with angiogenesis
(Dulak et al, 2008). To determine whether FECH plays a key role in
angiogenesis, we knocked FECH down in HRECs using siRNA
(Fig 2A and B) and monitored key angiogenic properties of HRECs
in vitro. FECH knockdown significantly reduced the proliferation of
HRECs (Figs 2C and EV2A). There was also a significant decrease in
migration of HRECs treated with FECH siRNA in a scratch-wound
assay (Fig 2D). Further, knocking down FECH in HRECs completely
abolished the tube formation ability of HRECs as monitored in a
Matrigel assay (Fig 2E).
To confirm the knockdown results, we also tested whether a
known pharmacological inhibitor of FECH shows antiangiogenic
properties in vitro. N-methyl protoporphyrin (NMPP), a competitive
inhibitor of FECH activity (Cole & Marks, 1984), also inhibited prolif-
eration, migration, and tube formation ability of HRECs in vitro
(Fig 2F–H). Similar results were seen in the primate choroidal
endothelial cell line, Rf/6a (Fig EV3A and B), broadening the rele-
vance of these findings. However, despite these potent antiprolifera-
tive effects, FECH knockdown and low-dose chemical inhibition were
not associated with significant apoptosis of these cells (Fig EV2B–D),
indicating a cytostatic rather than cytotoxic effect. This was further
confirmed in a washout experiment: HRECs resumed proliferation
after removal of NMPP (Fig EV2E). Moreover, FECH knockdown did
not inhibit proliferation of non-endothelial ocular cell lines ARPE-19
and 92-1 as well as macrovascular human umbilical vein endothelial
cells (HUVECs; Fig EV4A–C), indicating that FECH inhibition is not
associated with general cytotoxicity. Likewise, NMPP had negligible
antiproliferative effect on these cells and on retinoblastoma cell line
Y-79 (Fig EV4D–F and J). However, NMPP had similar antiprolifera-
tive potency on human brain microvascular endothelial cells
(BMECs) to its effects on HRECs (Fig EV4L). Together, these experi-
ments confirm that FECH function is required for angiogenesis
in vitro and that the angiostatic effects of FECH blockade are not cyto-
toxic and may be microvascular cell-specific.
Ferrochelatase is upregulated during neovascularization
Given the potent antiangiogenic effects of FECH knockdown we
observed in culture, we then explored whether FECH is associated
with neovascularization in vivo. We employed a mouse model of
laser-induced choroidal neovascularization (L-CNV). This widely
used model recapitulates some of the features of wet AMD
(Montezuma et al, 2009). FECH was overexpressed in and around
lesions during neovascularization in this model (Fig 3A); this over-
expression was seen throughout the retina, but especially in neoves-
sels (Fig 3B). More importantly, FECH expression was seen
throughout the retinal layers of human wet AMD patients analyzed
postmortem. In the subretinal layers including the choroid (the
origin of neovascularization in wet AMD), expression was signifi-
cantly increased compared to healthy, age-matched eyes (Fig 3C).
Ferrochelatase is required for neovascularization in vivo
Since FECH upregulation suggested a role for this protein in
neovascularization in the living eye, we asked whether decreased
FECH would inhibit this process. When L-CNV mice were treated
intravitreally with Fech-specific siRNA, there was a significant
decrease in choroidal neovascularization as compared with both
saline-treated control mice and control non-targeting siRNA-treated
mice (Fig 3D). To confirm these findings in a genetic model, we
turned to the Fechm1Pas mouse, which carries a partial loss-of-func-
tion M98K point mutation in the Fech gene (Tutois et al, 1991). In
M98K heterozygotes, FECH activity is 45–65% of normal, while in
homozygotes, activity is < 10% of normal (Boulechfar et al,
1993). We observed a reduction in L-CNV in heterozygous
Fechm1Pas mutant mice compared with wild type, and this reduc-
tion was even more pronounced in the Fechm1Pas homozygotes
(Fig 3E). These in vivo experiments confirm the clinical relevance
of FECH in neovascularization, and the value of targeting this
enzyme to block this process.
Ferrochelatase-targeting therapy treats neovascularization
The FDA-approved antifungal drug, griseofulvin, has been in clinical
use for over half a century (Petersen et al, 2014). The primary anti-
fungal mechanism of this compound is as a microtubule inhibitor
(Borgers, 1980). However, an unexpected off-target effect of this
drug is inhibition of FECH (Holley et al, 1990; Brady & Lock, 1992;
Martinez et al, 2009). Griseofulvin alkylates the heme prosthetic
group of cytochrome P450 in vivo, forming NMPP, the FECH active-
site inhibitor (Liu et al, 2015). Taking advantage of this property,
we treated HRECs with griseofulvin and observed dose-dependent
antiproliferative effects, inhibition of migration, and inhibition of
tube formation (Fig 4A–C) similar to those observed after FECH
knockdown. The concentrations of griseofulvin needed to have
effects on endothelial cells were higher than those seen with NMPP
(Fig 2F–H), likely due to incomplete alkylation of heme in griseoful-
vin-treated cells. However, this concentration (~10 lM or ~3.5 ng/
ml) is 2.75 logs less than that attained in plasma during antifungal
treatment of humans (1–2 lg/ml; Epstein et al, 1972), suggesting
that efficacy in vitro can be achieved in a clinically attainable
concentration range. Moreover, effective antiangiogenic concentra-
tions of griseofulvin were not associated with apoptosis (Fig EV2F)
of HRECs and could be washed out with resumption of proliferation
(Fig EV2G). Griseofulvin did not have pronounced antiproliferative
effects on other ocular cell types or HUVECs (Fig EV4G–I and K),
but did affect proliferation and tube formation of Rf/6a choroidal
endothelial cells (Fig EV3C and D) and proliferation of BMECs
(Fig EV4M). In addition, griseofulvin inhibited formation of
microvascular sprouts in the choroidal sprouting assay, an ex vivo
model of choroidal angiogenesis (Fig 4D). It also performed simi-
larly in an ex vivo retinal endothelial sprouting assay, showing
pronounced antiangiogenic activity (Fig 4E). Thus, griseofulvin
specifically inhibits the growth of microvascular endothelial cells,
including those of the retina and choroid.
Spurred by these findings, we tested griseofulvin as a therapy for
L-CNV. Ad libitum feeding of ≥ 0.5% (w/w) griseofulvin to mice
has previously been demonstrated to induce inhibition of FECH
(Brady & Lock, 1992). Excitingly, such oral treatment of L-CNV mice
decreased neovascularization (Figs 5A–C and EV5A and B); simi-
larly, dose-dependent results were seen when griseofulvin was
intravitreally injected instead; this is the standard delivery route for
existing anti-VEGF agents (Fig 5D–F). Both delivery routes had
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Figure 2. FECH is an essential protein for angiogenesis in vitro.
A FECH is knocked down using specific siRNAs as confirmed by immunoblot.
B Quantification of FECH knockdown. *P = 0.0319, two-tailed unpaired Student’s t-test (n = 3 per group).
C Proliferation of HRECs was monitored in presence or absence of FECH-specific siRNA. ***P = 0.0004, two-tailed unpaired Student’s t-test (n = 6 per group).
D Scratch-wound migration assay was performed with or without FECH knockdown in HRECs. **P = 0.0077, two-tailed unpaired Student’s t-test (n = 3 per group).
Dotted lines indicate borders of scratch at time zero.
E Ability of HRECs to form tubes in vitro on Matrigel was monitored after knocking down FECH. ***P = 0.0003, two-tailed unpaired Student’s t-test (n = 4 per group).
F The effect of NMPP, a specific inhibitor of FECH activity, on in vitro proliferation was measured using an AlamarBlue assay (n = 3 per dose).
G Migration of HRECs in presence of different doses of NMPP was measured using a scratch-wound assay. ****P = 0.0001 compared to DMSO-treated sample, ANOVA
with Dunnett’s post hoc tests (n = 3 per group). Dotted lines indicate borders of scratch at time zero.
H Ability of HRECs to form tubular structures in Matrigel was monitored after NMPP treatment. ****P = 0.0001 compared to DMSO-treated sample, ANOVA with
Dunnett’s post hoc tests (n = 4 per group).
Data information: Graphs show mean  SEM. Representative results from at least three independent experiments. Scale bars = 1 mm.
Source data are available online for this figure.
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similar maximal effects. We also tested whether intravitreal griseo-
fulvin could synergize with anti-VEGF164 antibody treatment, equiv-
alent to the standard of care. We observed a modest additive effect
of low-dose anti-VEGF164 with 50 lM griseofulvin (Fig EV5C),
perhaps warranting further exploration of this combination therapy.
Ferrochelatase depletion decreases the VEGF receptor via eNOS
In order to understand how FECH contributes to angiogenesis, we
knocked down FECH in HRECs and monitored levels of endothelial
nitric oxide synthase (eNOS), a key angiogenesis regulator that
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Figure 3. FECH is an essential protein for angiogenesis in vivo.
A Whole mount staining of L-CNV mouse choroid stained with an antibody against FECH (red) and with agglutinin (green) to label neovascularization. Scale bar = 50 lm.
B Sections of L-CNV and untreated mouse eyes stained with an antibody against FECH (red), with agglutinin (green) to label neovascularization and with DAPI to label
nuclei (blue). Retinal layers indicated: GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. Scale bar = 20 lm.
C Immunostaining of sections of eyes from an 89-year-old wet AMD patient and age-matched control using an antibody against FECH (red). The nuclei of cells are
stained blue with DAPI. Retinal layers indicated: GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. Scale bar = 20 lm. The staining intensity
of subretinal FECH, where CNV occurs, was quantified in human subjects (n = 3 per group). *P = 0.0269, two-tailed unpaired Student’s t-test.
D Whole mount staining of RPE/choroid isolated from L-CNV mice treated with Fech-specific siRNA. The choroidal vasculature was stained with agglutinin conjugated
with Alexa Fluor 555 (red), and the neovascular area around the lesions was quantified. *P = 0.044; **P = 0.0038, ANOVA with Tukey’s post hoc tests (n = 5–9 per
group). Scale bar = 50 lm.
E Whole mount staining of RPE/choroid isolated from mice wild-type (WT), heterozygous (Hetero), or homozygous (Homo) for the Fechm1Pas point mutation that
underwent L-CNV. The choroidal vasculature was stained with agglutinin conjugated with Alexa Fluor 555 (red), and the neovascular area around the lesions was
quantified. *P = 0.015; **P = 0.0037 versus WT, ANOVA with Tukey’s post hoc tests (n = 9–13 per group). Scale bar = 50 lm.
Data information: Graphs show mean  SEM.
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Figure 4. Chemical inhibition of FECH inhibits angiogenesis in vitro.
A The effect of griseofulvin, an FDA-approved drug that inhibits FECH activity, on proliferation of HRECs in vitro. (n = 3 per dose).
B Migration of HRECs in presence of griseofulvin was measured in a scratch-wound assay. ****P = 0.0001, ANOVA with Dunnett’s post hoc tests (n = 3 per group).
Dotted lines indicate borders of scratch at time zero.
C Ability of HRECs treated with griseofulvin to form tubular structures in Matrigel was monitored and analyzed using ImageJ. **P = 0.0082, ANOVA with Dunnett’s
post hoc tests (n = 6 per group).
D The mouse choroidal sprouting assay was used to further measure the antiangiogenic potential of griseofulvin. Representative phase contrast images and
quantitative analysis of choroidal endothelial sprouting. **P = 0.0018; ****P = 0.0001 versus DMSO at same time point, two-way repeated measures ANOVA with
Dunnett’s post hoc tests (n = 3–4 per group).
E The ex vivo murine retinal angiogenesis assay was also used to measure the antiangiogenic potential of griseofulvin. Representative phase contrast images and
quantitative analysis of retinal endothelial sprouting. ****P = 0.0001 versus DMSO at same time point, two-way repeated measures ANOVA with Dunnett’s post hoc
tests (n = 5 per group).
Data information: Graphs show mean  SEM, and the images are representative results from at least two independent experiments. Scale bars = 1 mm.
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requires a heme cofactor for its activity to produce the proangiogenic
molecule nitric oxide (NO; Fo¨rstermann & Mu¨nzel, 2006). Immuno-
blot of HRECs treated with FECH siRNA showed significantly
decreased levels of eNOS (Fig 6A). Further, NOS activity was
decreased in FECH knockdown HRECs as compared to negative
control siRNA-treated cells (Fig 6B). To assess hemylation of eNOS,
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we used a hemin pull-down assay. Only hemoproteins in the apo
form (enzyme lacking the heme cofactor) will bind to hemin agarose
beads. Despite the overall decrease in eNOS levels, we observed that
the remaining eNOS was in the apo form (Fig 6C) when HRECs were
treated with NMPP, the specific inhibitor of FECH activity. As NO,
the product of eNOS enzymatic activity, stabilizes hypoxia inducible
factor (HIF) 1a (Sandau et al, 2001), we also monitored levels of this
key mediator of angiogenesis after knocking down FECH in HRECS.
FECH knockdown decreased protein levels HIF-1a (Fig 6D).
Since VEGF is a major proangiogenic stimulus, we monitored
key events of VEGF signaling after knocking down FECH. We
observed a profound decrease in (activating) phosphorylation of the
major VEGF receptor VEGFR2 as well as total VEGFR2 protein levels
in FECH knockdown cells when cultured in basal medium contain-
ing VEGF165 (Fig 6E), although production of VEGFA mRNA was
unchanged (Appendix Fig S2). Interestingly, levels of related recep-
tors VEGFR1 and neuropilin 1 were not affected by FECH depletion
(Fig 6E). The protein levels of eNOS and VEGFR2 were partially
rescued after treating FECH knockdown cells with exogenously
added hemin (a stable form of heme, the enzymatic product of
FECH; Fig 6E). The decreased levels of eNOS, VEGFR2, and HIF-1a
after FECH knockdown were not due to general translational inhibi-
tion: There was no difference in phosphorylation levels of eIF-2a in
FECH siRNA-treated cells (Fig 6F).
Discussion
Understanding the molecular events of pathological angiogenesis is
key to developing novel therapeutics for neovascular eye diseases
such as proliferative diabetic retinopathy, retinopathy of prematu-
rity, and wet AMD. Currently, the drug pipeline for these diseases is
dominated by anti-VEGF biologics (Kaiser, 2013). Even though these
drugs have been successfully used to halt the progression of disease
in wet AMD and proliferative diabetic retinopathy patients, there is
a significant patient population (~30%) who are resistant to these
treatments (Folk & Stone, 2010; Prasad et al, 2010). Hence diversifi-
cation of the drug pipeline with novel therapeutic agents with dif-
ferent mechanisms of action is required (Smith & Kaiser, 2014).
Toward this end, we used a forward chemical genetics approach
using an antiangiogenic natural product, cremastranone, to uncover
new drug targets for angiogenesis.
Using a series of biochemical, in vitro, and in vivo studies, we
have determined that FECH is a key protein involved in ocular
angiogenesis that can be exploited for developing novel antiangio-
genic drugs. A photoaffinity-based chromatographic technique iden-
tified FECH as a protein binding partner of cremastranone.
Although, like other natural products, cremastranone likely exhibits
polypharmacology (Sulaiman et al, 2014), our data indicate that it
exerts its antiangiogenic activity at least partially through inhibition
of FECH activity.
Interestingly, FECH is a bona fide mediator of angiogenesis. Lack
of FECH activity caused inhibition of angiogenesis both in vitro and
in vivo. More importantly, only retinal and choroidal microvascular
endothelial cell proliferation was inhibited in vitro while other ocular
cell types tested did not show significant decreases in cell prolifera-
tion after FECH knockdown. Even macrovascular HUVECs were not
as profoundly affected by FECH depletion as the microvascular
HRECs and Rf/6a cells. These data reveal that microvascular
endothelial cells are particularly sensitive to FECH depletion. The
lack of cytotoxic effects of FECH inhibition leads to consideration of
FECH as a novel therapeutic target for ocular neovascular disease,
possibly with minimal side effects. Supporting this latter assertion, in
the genetic disease erythropoietic protoporphyria (EPP), FECH activ-
ity is markedly reduced, but EPP patients infrequently present severe
symptoms apart from skin photosensitivity (Lecha et al, 2009). It
may be possible to tune FECH activity to minimize side effects while
maximizing antiangiogenic effects: Heterozygous Fechm1Pas mice do
not display an EPP phenotype, despite reduced FECH function
(Boulechfar et al, 1993), but do show reduced choroidal neovascular
response (this study). Neovascularization in human EPP patients has
not been studied extensively, although a single case report describes
an ocular phenotype of idiopathic optic neuropathy in an EPP
patient, not conclusively related to the disease (Tsuboi et al, 2007).
Excitingly, we have shown that the FDA-approved antifungal
drug and FECH inhibitor griseofulvin inhibited ocular angiogenesis
in the L-CNV mouse model when administered orally. Griseofulvin
has been used widely to treat fungal infections and is taken orally,
often for months or years (Petersen et al, 2014; Liu et al, 2015). An
off-target side effect of this therapy is that griseofulvin causes the
formation of NMPP, along with other alkylated porphyrins, primarily
in the liver (Liu et al, 2015). NMPP in turn acts as an active-site inhi-
bitor of FECH (Cole & Marks, 1984). As with genetic reduction in
function of FECH, apart from skin photosensitivity, no other major,
common side effects are reported with systemic griseofulvin treat-
ment of humans (Elewski & Tavakkol, 2005; Grover et al, 2012).
The fact that griseofulvin-fed mice showed decreased ocular
neovascularization as compared to control mice is important as
▸Figure 5. Antifungal drug griseofulvin inhibits ocular neovascularization in vivo.A Mice were fed ad libitum with 0.5 and 1% griseofulvin for 1 week prior to and throughout laser-induced choroidal neovascularization (L-CNV) development. CNV was
monitored by optical coherence tomography (OCT) of mouse eyes in vivo. Retinal layers indicated: GCL, ganglion cell layer; ONL, outer nuclear layer; RPE, retinal
pigment epithelium. CNV is observed as a broadening of the hyper-reflective tissues toward the bottom of the images, with corresponding deformation of the inner
retinal layers.
B Confocal imaging of CNV lesions ex vivo stained with agglutinin conjugated with Alexa Fluor 555 (red).
C The lesion volumes were measured from confocal images. *P = 0.048 and 0.013 versus vehicle, ANOVA with Dunnett’s post hoc tests (n = 15–17 eyes per group).
D The effect of a single intravitreal injection of griseofulvin at time of laser treatment on choroidal neovascularization in the L-CNV model as monitored by OCT. Retinal
layers indicated: GCL, ganglion cell layer; ONL, outer nuclear layer; RPE, retinal pigment epithelium.
E Confocal imaging of CNV lesions ex vivo stained with agglutinin conjugated with Alexa Fluor 555 (red).
F The CNV lesion volumes were measured from confocal images. *P = 0.015; ****P = 0.0001 versus vehicle, ANOVA with Dunnett’s post hoc tests (n = 11–13 eyes per group).
Data information: Graphs show mean  SEM. Anti-VEGF164 is a positive control antibody therapy. Scale bars for OCT images and immunostained choroids are 100 lm
and 50 lm, respectively.
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currently there are no oral drugs available for the treatment of
ocular neovascularization. The current approved drugs (anti-VEGF
biologics) are all delivered intravitreally. If side effects were
manageable, an oral therapy would be appealing. However, since
griseofulvin was also effective when delivered intravitreally, combi-
nation intravitreal therapies of this drug with anti-VEGF biologics
are also an interesting possibility to increase efficacy and decrease
side effects of existing treatments. Moreover, griseofulvin offers the
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Figure 6. FECH depletion suppresses VEGFR2 via eNOS and HIF-1a.
A Protein levels of eNOS were measured by immunoblot after knocking down FECH in HRECs. ****P = 0.0001, two-tailed unpaired Student’s t-test (n = 3 per group).
B Production of NO was monitored using a diaminofluorescein-2-diacetate-based fluorometric assay. ****P = 8 × 1010, two-tailed unpaired Student’s t-test (n = 6
per group).
C Immunoblots from hemin pull-down assay (to detect apo-eNOS) using proteins extracted from HRECs treated with DMSO or 10 lM NMPP.
D HIF-1a was measured by immunoblot after knocking down FECH in HRECs. *P = 0.043, two-tailed unpaired Student’s t-test (n = 3 per group).
E Protein levels of eNOS, neuropilin, VEGFR1, and VEGFR2, plus phosphorylation of VEGFR2 at Tyr1175 in HRECs after treatment with negative control or FECH siRNAs
and/or hemin (0.1 lM) in complete medium were monitored by immunoblot. ***P = 0.0005; *P = 0.0426 (for eNOS); **P = 0.0069 versus negative siRNA (for
VEGFR2), ANOVA with Tukey’s post hoc tests (n = 3 per group).
F Phosphorylation of eIF2a at Ser51 and protein levels of Hsp90 were measured by immunoblot after knocking down FECH in HRECs.
Data information: The figures are representative from at least three independent experiments and the graphs show mean  SEM.
Source data are available online for this figure.
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promise of low-cost treatment if shown efficacious in clinical trials.
There are also prospects for novel FECH inhibitors as therapy: We
have developed cremastranone analogs that may also act through
FECH (Basavarajappa et al, 2015), and recently, the drugs vemu-
rafenib (Savitski et al, 2014) and salicylic acid (Gupta et al, 2013),
as well as a lipid-derived probe compound (Niphakis et al, 2015),
were all shown to bind to FECH, suggesting that this protein has
many potential binding clefts and is therefore likely druggable with
novel compounds.
FECH is the only known enzyme in humans to synthesize heme,
and any loss of activity of this enzyme might result in intracellular
heme deficiency (Dailey et al, 2000). Heme serves as either a pros-
thetic group for many enzymes or as a signaling molecule regulating
expression of genes involved in cell differentiation, proliferation,
and signal transduction (Mense & Zhang, 2006). FECH knockdown
decreased protein levels of eNOS, HIF-1a and VEGFR2, key players
promoting angiogenesis, in HRECs. As eNOS is a heme-dependent
enzyme, FECH knockdown directly affects the stability and activity
of eNOS. The product of the eNOS enzyme, NO, induces angiogene-
sis (Ziche & Morbidelli, 2000), partly by stabilizing HIF-1a under
normoxia (Sandau et al, 2001). This explains the logic behind the
decreased protein levels of HIF-1a in FECH knockdown cells with
decreased eNOS activity. HIF-1a is a transcription factor that regu-
lates the expression of a range of proangiogenic proteins. VEGFR2,
the major tyrosine kinase receptor of VEGF165, is upregulated under
hypoxia (Tuder et al, 1995; Takagi et al, 1996). Thus, the decreased
levels of VEGFR2 in HRECs after FECH siRNA treatment can be
linked to decreased HIF-1a. Taken together, low protein levels of
VEGFR2 (and thus angiogenesis) in FECH-deficient HRECs can be
directly attributed to loss of heme in cells and the resultant decrease
in levels of eNOS enzyme. VEGFR2 depletion in turn further
suppresses eNOS levels. The rescue of VEGFR2 and eNOS expres-
sion by addition of exogenous hemin, a stable form of heme, further
supports this mechanism.
Our findings reveal a previously undocumented, central role of
FECH in ocular angiogenesis. They provide a rationale for clinical
testing of griseofulvin in neovascular eye disease. In addition, it will
be valuable to develop novel, FECH-targeted therapies for treating
the debilitating ocular diseases caused by neovascularization.
Materials and Methods
Materials
EBM-2 and IMDM growth media were purchased from Lonza (Walk-
ersville, MD, USA). HRECs, BMECs, and Attachment Factor were
purchased from Cell Systems (Kirkland, WA, USA). Clonetics
HUVECs were purchased from Lonza. All endothelial cells were
used between passages 5 and 8. Endothelial growth medium (EGM-
2) was prepared by mixing the contents of an EGM-2 “Bullet Kit”
(Cat no. CC-4176) with endothelial basal medium (EBM; Lonza).
Rf/6a cells were obtained from ATCC (Manassas, VA, USA) and
grown in EMEM. Y-79 cells were grown in RB medium (Basavara-
jappa et al, 2015), while 92-1 (Basavarajappa et al, 2015) and
ARPE-19 (ATCC) cells were grown in RPMI and DMEM, respec-
tively, supplemented with 10% FBS and 1% penicillin–streptomycin
as described earlier (Basavarajappa et al, 2015); identity was
confirmed by STR profiling and cells were monitored regularly for
mycoplasma contamination. Click-iT TUNEL Alexa Fluor 594 imag-
ing assay kit (Cat no. C10246) was purchased from Molecular
Probes (Eugene, OR, USA). Monoclonal antibodies against a-tubulin
(DM1A) and b-actin (AC40), protoporphyrin IX, 5-aminolevulinic
acid, hemin, hemin agarose beads, griseofulvin, and L-arginine were
purchased from Sigma-Aldrich (St. Louis, MO, USA). N-methyl
protoporphyrin (NMPP) and the primary antibodies against FECH
(A-3 and C20) were obtained from Santa Cruz (Santa Cruz, CA,
USA). Antibodies against cleaved caspase 3 (5A1E), phospho-
VEGFR2 (Tyr 1175) (19A10), phospho-eIF2a (Ser 51) (9721), eIF2a
(9722), and eNOS (49G3) were from Cell Signaling (Danvers, MA,
USA). Anti-HIF-1a (241809), VEGFR1 (AF321), and anti-VEGF164
(AF-493-NA) antibodies were purchased from R&D systems (Min-
neapolis, MN, USA). The antibody against neuropilin 1 (ab81321)
was purchased from Abcam (Cambridge, MA, USA). Secondary anti-
bodies were from Thermo Fisher Scientific (Pittsburgh, PA, USA).
The Trizol, TaqMan probes, qPCR master mix, and 5-ethynyl-2ʹ-
deoxyuridine (EdU) incorporation assay kit were procured from Life
Technologies (Carlsbad, CA, USA). The iScript reverse transcriptase
was from Bio-Rad (Hercules, CA, USA). AbD Serotec (Kidlington,
UK) was the source of the alamarBlue, while BD Biosciences (San
Jose, CA, USA) supplied the Matrigel. 4,5-Diaminofluorescein diac-
etate (DAF-2 diacetate) was purchased from Cayman Chemicals
(Ann Arbor, MI, USA). ECL Prime Western blotting detection
reagent was purchased from GE Healthcare (Buckinghamshire, UK).
Preparation of photoaffinity reagents
Synthesis and characterization of affinity reagents 2 and 3 was
performed as described (Lee et al, 2016). Compound 2 contains a
trimethoxy derivative of cremastranone that is more synthetically
tractable, but which maintains good cellular potency and selectivity,
both as homoisoflavonoid (Basavarajappa et al, 2015) and when
incorporated into the affinity reagent (Lee et al, 2016). Compounds
1 and 4 were synthesized as described (Basavarajappa et al, 2014;
Lee et al, 2014), with purity > 95%. For pull-downs, Neutravidin
agarose beads (1 ml of 50% slurry) were washed three times in
buffer A containing 25 mM Tris–HCl pH 7.4, 150 mM NaCl, 2.5 mM
sodium pyrophosphate, 1 mM phenylmethylsulfonyl fluoride
(PMSF), 0.1 mM sodium orthovanadate, 10 lg/ml aprotinin, and
10 lg/ml leupeptin. The beads were then incubated with 100 lM
affinity or control reagents 2 or 3 overnight at 4°C with rotation.
The beads were blocked using 1 mM biotin solution prepared in
buffer A for 1 h followed by incubation with 1 mg/ml cytochrome c
solution for 1 h at 4°C. The beads were then washed three times
with buffer A and resuspended in 1 ml.
Photoaffinity pull-down experiments
Flash-frozen porcine brain (20 g) obtained from the Purdue-Indiana
University School of Medicine Comparative Medicine Program was
homogenized in 50 ml buffer A using a tissue homogenizer. Porcine
brain was chosen as it is readily available and a rich source of
protein. The homogenate was centrifuged at 2,000 g for 5 min. The
supernatant (S1) was then homogenized by 50 strokes of a Dounce
homogenizer followed by 10 min sonication with amplitude of 60%
in cycles of 10 s sonication on and 40 s sonication off (Q125 from
EMBO Molecular Medicine ª 2017 The Authors
EMBO Molecular Medicine Ferrochelatase in neovascularization Halesha D Basavarajappa et al
10
Published online: April 4, 2017 
QSonica, Newtown, CT, USA). The lysate was then centrifuged at
11,000 g for 30 min. The resulting supernatant (S2) and pellet (P2)
fractions were both collected. The P2 pellet was resuspended in
buffer B: 1% Triton X-100 + buffer A and then homogenized by 25
strokes of a Dounce homogenizer and centrifuged at 11,000 g for
30 min; supernatant (S3) was collected. Both S2 and S3 supernatants
were equally divided, and each fraction was incubated with 500 ll
photoaffinity or control reagent conjugated to Neutravidin beads for
75 min at 4°C with shaking.
The beads were collected by centrifugation at 500 g for 5 min,
then resuspended in 1 ml of buffer B and irradiated with 365 nm
UV light (Mercury bulb H44GS100 from Sylvania in a Blak-Ray
100A long-wave UV lamp with output of 25 mW/cm2 at sample
distance) in a 60-mm Petri dish for 30 min at 4°C. The beads were
then washed two times in buffer B, followed by three washes in
high-salt buffer containing 25 mM Tris–HCl pH 7.4, 350 mM NaCl,
1% Triton X-100, and 1 mM PMSF. The beads were then washed
again in salt-free buffer containing 25 mM Tris–HCl, 1% Triton
X-100, and 1 mM PMSF. After 5-min incubation, the beads were
collected and any residual liquid was removed using a Hamilton
syringe. The Neutravidin beads were then heated in 300 ll of 2×
SDS–PAGE gel loading dye containing 30 ll of 2-mercaptoethanol
for 10 min at 70°C to release the bound proteins. After heating, the
contents were allowed to cool and after a quick spin the eluate was
collected using a Hamilton syringe. The eluates were then analyzed
in 4–20% gradient SDS–PAGE, and the protein bands were visual-
ized using silver staining (Corson et al, 2011). The protein bands
pulled down specifically by photoaffinity reagent were excised from
the silver-stained SDS–PAGE gel and analyzed by mass spectrometry
(IUSM Proteomics Core). Using SequestTM algorithms and the swine
database (UniProt), the identities of the pulled-down proteins were
confirmed (Appendix Fig S1).
For competition experiments, S2 and S3 supernatants were incu-
bated with affinity reagent-Neutravidin beads in the presence of
1 mM cremastranone isomer SH-11052 (4) (Basavarajappa et al,
2014) and then processed as described above.
Recombinant FECH
Recombinant human FECH protein was purified as described previ-
ously (Dailey et al, 1994). Briefly, Escherichia coli JM109 cells trans-
formed with plasmid pHDTF20 encoding recombinant human FECH
were grown in Circlegrow medium containing 100 lg/ml ampicillin
for 20 h at 30°C. The cells were harvested and resuspended in solubi-
lization buffer (50 mM Tris-MOPS pH 8.0, 1% sodium deoxycholate,
100 mM KCl, and 1 mM PMSF). The cell suspension was sonicated
and then ultracentrifuged at 45,000 g for 30 min. The supernatant
was subjected to cobalt-affinity chromatography, and the column
was washed with solubilization buffer containing 20 mM imidazole.
The protein was eluted with 250 mM imidazole in solubilization
buffer. The protein eluate was then dialyzed in solubilization buffer
containing 10% glycerol before storage at 4°C. Recombinant protein
(200 lg) was used in pull-down experiments as above.
Immunoblot assay
Immunoblots were performed as described previously (Basavara-
jappa et al, 2014). Briefly, cell lysates were prepared by incubating
the cells for 10 min at 4°C in NP-40 lysis buffer (25 mM HEPES
pH 7.6, 150 mM NaCl, 1% NP-40, 10% glycerol, 1 mM sodium
orthovanadate, 10 mM NaF, 1 mM PMSF, 10 lg/ml aprotinin,
1 lM pepstatin, 1 lM leupeptin) and then centrifuged at 12,000 g
for 15 min at 4°C. Supernatant was collected, and protein concen-
tration was determined using a Bradford assay. Equal amounts of
total protein (40 lg) from each sample were resolved by 10%
SDS–PAGE and transferred onto PVDF membranes. Proteins were
immunoblotted with antibodies against FECH (clone A-3; 1:1,000
dilution), a-tubulin (1:1,000), VEGFR1 (1:500), phospho-VEGFR2
(1:500), VEGFR2 (1:500), phospho-eIF2a (1:500), eIF2a (1:500),
HIF-1a (1:500), neuropilin 1 (1:500), b-actin (1:1,000), or eNOS
(1:500). All of the dilutions were made in Tris-buffered saline-
0.05% Tween-20 buffer containing 2% bovine serum albumin
(BSA).
siRNA knockdown of FECH in cells
Cells were grown in 6-well plates until 80% confluency was
achieved. Lipofectamine RNAiMAX reagent (7.5 ll, Life Technolo-
gies) mixed with 30 pmol of siRNAs was added to each well accord-
ing to the protocol recommended by the manufacturer. For FECH
knockdown, 15 pmol each of two siRNAs (SASI_Hs01_00052189
and SASI_Hs01_00052190; Sigma) was used, and for negative
control, MISSION siRNA Universal negative control was used.
Fresh EGM-2 medium was added to the plate 24 h after transfection,
and cells were used 48 h after transfection for further experiments
except for the proliferation time course, for which 24 h after trans-
fection the cells were trypsinized and seeded in a 96-well plate.
Cell proliferation assay
Proliferation of cells was monitored as described before (Basavara-
jappa et al, 2014). Briefly, 2,500 cells (after FECH knockdown in
some experiments) in 100 ll of growth medium were plated in each
well of 96-well clear-bottom black plates and incubated for 24 h.
Griseofulvin, NMPP, or DMSO vehicle (final DMSO concentration of
1%) was added, and the plates were incubated for 44 h in 100 ll
media at 37°C and 5% CO2. For washout experiments, 1,500 cells
were initially plated, and drug-containing medium was removed
after 48 h and cells incubated in fresh growth medium for a further
24 or 48 h. AlamarBlue reagent (11.1 ll) was added to each well of
the plate and 4 h later fluorescence readings were taken at excita-
tion and emission wavelengths of 560 nm and 590 nm, respectively,
using a Synergy H1 plate reader (BioTek, Winooski, VT, USA). For
dose–response experiments, GI50 was calculated using GraphPad
Prism v. 7.0.
Migration assay
The migration of HRECs was monitored as described before
(Basavarajappa et al, 2014). Briefly, HRECs were grown until con-
fluency in 6-well plates and then serum starved overnight in EBM-2
medium. Using a sterile 10-ll tip, a scratch was introduced in each
well and fresh EGM-2 medium containing DMSO or different
concentrations of compounds was added to the wells. For knock-
down experiments, the scratch was introduced 48 h after transfec-
tion and fresh medium was added to the wells. Photographs of the
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wells were taken at different time points, and the number of
migrated cells into the scratched area was manually counted.
In vitro Matrigel tube formation assay
The ability of HRECs and Rf/6a cells to form tubes in vitro was moni-
tored as described before (Basavarajappa et al, 2015). Briefly, cells
were treated with the indicated concentrations of compounds or
DMSO or siRNAs for 48 h and then 15,000 cells in 100 ll of growth
medium containing siRNAs, DMSO, or compounds were added to
each well of a 96-well plate that was pre-coated with 50 ll of Matrigel
basement membrane. Photographs of each well at different time
points were taken to measure the tube formation using the Angiogen-
esis Analyzer plugin in ImageJ software (v.1.48; http://image.bio.me
thods.free.fr/ImageJ/?Angiogenesis-Analyzer-for-ImageJ.html).
Animals
All animal experiments were approved by the Indiana University
School of Medicine Institutional Animal Care and Use Committee
and followed the guidelines of the Association for Research in
Vision and Ophthalmology Statement for the Use of Animals in
Ophthalmic and Visual Research. Wild-type female C57BL/6J mice,
6–8 weeks of age or timed pregnancies, were purchased from Jack-
son Laboratory (Bar Harbor, ME) and housed under standard condi-
tions (Wenzel et al, 2015). Fechm1Pas mice (Tutois et al, 1991) were
purchased from Jackson Laboratory on a BALB/c background and
backcrossed into C57BL/6J; mixed-sex littermates from a subse-
quent brother–sister mating were used for experiments at 6–8 weeks
of age. Mice were anesthetized for all procedures by intraperitoneal
injections of 80 mg/kg ketamine hydrochloride and 10 mg/kg xyla-
zine. Sample sizes were based on power analyses, and treatments
were randomly assigned by cage.
L-CNV model
L-CNV was generated as described previously (Lambert et al, 2013;
Poor et al, 2014; Sulaiman et al, 2015). Studies were powered to
have an 80% chance of detecting effect size differences of 50%,
assuming 30% variability, a = 0.05. Briefly, eyes were dilated using
1% tropicamide, then underwent laser treatment using 50 lm spot
size, 50 ms duration, and 250 mW pulses of an ophthalmic argon
green laser, wavelength 532 nm, coupled to a slit lamp. Where indi-
cated, intravitreal injections of PBS vehicle, siRNA (1.25 lM final
intravitreal concentration), griseofulvin (50, 100 lM, final intravit-
real concentrations), anti-VEGF164 antibody (0.2, 1, 5 ng delivered),
or combinations of griseofulvin and anti-VEGF164 antibody, as indi-
cated, were given in a 0.5 ll volume at the time of laser treatment.
Eyes were numbed with tetracaine solution before the injection, and
triple antibiotic ointment was used immediately after the injection
to prevent infection. A masked researcher undertook imaging and
analysis to avoid bias. One week after laser treatment, mice under-
went optical coherence tomography using a Micron III imager
(Phoenix Research Labs, Pleasanton, CA, USA) and CNV lesions
were quantified as ellipsoids as described (Sulaiman et al, 2015).
Two weeks after laser treatment, eyes were enucleated and fixed,
choroidal flat mounts prepared, and vasculature stained with
rhodamine-labeled Ricinus communis agglutinin I (Vector Labs,
Burlingame, CA, USA), followed by confocal Z-stack imaging (LSM
700, Zeiss, Thornwood, NY, USA) to estimate lesion volume. The
sum of the stained area in each section, multiplied by the distance
between sections (3 lm), gave the CNV lesion volume.
Immunostaining
Human donor eyes from wet AMD patients or age-matched controls
were obtained from the National Disease Research Interchange
(NDRI; Philadelphia, PA) with full ethical approval for use in
research. NDRI obtains informed consent for all donor material
(http://ndriresource.org/for-donors-patients) and all procedures
conform to the principles set out in the WMA Declaration of Helsinki
and the Department of Health and Human Services Belmont Report.
All sample tissues were anonymized prior to receipt in the labora-
tory. Mouse eyes were harvested 14 days after L-CNV induction. The
eyes were enucleated and fixed in 4% paraformaldehyde/PBS over-
night. The anterior segment, lens, and vitreous humor were
removed, and the posterior eye cups were prepared for standard
paraffin sections or retinal flat mounts. Deparaffinized sections were
treated with rodent deblocker (Biocare Medical, Concord, CA, USA)
for antigen retrieval. The sections or flat mounts were washed with
PBS then permeabilized with 0.3% Triton X-100 and nonspecific
binding blocked by 10% normal goat serum plus 1% BSA in PBS.
They then received primary antibody (polyclonal anti-FECH (clone
C20)) at 1:500 for 16 h at 4°C. After primary incubation, sections or
whole mounts were washed and incubated for 1.5 h at room temper-
ature with secondary antibody (Cy3-conjugated goat anti-rabbit IgG,
1:600) at 4°C with 0.1% Triton X-100. We used a vascular-specific
lectin (Ricinus communis agglutinin I; Vector Laboratories, Inc.)
conjugated to Alexa Fluor 488 to label the retinal vasculature. This
was incubated for 30 min at room temperature in 1:400 of 10 mM
HEPES plus 150 mM NaCl and 0.1% Tween-20. After washing, spec-
imens were mounted in aqueous mounting medium (VectaShield;
Vector Laboratories, Inc.) and coverslipped for observation by confo-
cal microscopy and quantification where noted by a masked investi-
gator using ImageJ software. All microscopic images in a given panel
were acquired with identical exposure settings.
Choroidal sprouting assay
Choroidal sprouting was assessed as described (Sulaiman et al,
2016). Briefly, pieces of choroid–sclera dissected from mouse eyes
were embedded in Matrigel and grown in EGM-2 medium plus antibi-
otics for 72 h to allow sprouting to initiate. The indicated concentra-
tions of griseofulvin (in DMSO, final DMSO concentration 1%) were
added and growth allowed to proceed for 48 h. Images were taken
and growth quantified by measuring the distance from the edge of the
choroidal piece to the growth front in four directions per sample.
Retinal endothelial cell sprouting assay
An ex vivo murine retinal angiogenesis assay (EMRA) was
performed according to the previously published protocol (Rezzola
et al, 2013) with slight modifications. Briefly, retinal fragments were
isolated from adult C57BL/6J mice (3.5–4.5 weeks old) and embed-
ded in fibrin gel [containing bovine fibrinogen (4 mg/ml), aprotinin
(5 lg/ll), and bovine thrombin (500 mU/ml)] in serum-free DMEM
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and allowed to gel at 37°C. After clotting for 20–30 min, 400 ll of
DMEM containing 10% FBS and human VEGF165 (100 ng/well) was
added and replaced after 3 days. After day 7, medium was replaced
with DMEM containing 2% FBS plus VEGF165 (100 ng/well) and
treated with griseofulvin (20 and 40 lM) or vehicle control (DMSO,
0.5% final concentration). Endothelial sprouting was monitored and
photographed daily until day 3 after treatment. Image analysis of
the retinal endothelial sprouting was performed manually using
ImageJ software, and quantification was performed of least six
regions of interest per treatment per time point. Endothelial cell
sprouting was represented as sprouting distance in pixels.
Griseofulvin feeding
Mice were fed griseofulvin for a total of 3 weeks, with chow
changed every 2–3 days. Standard mouse chow (5 g/mouse/day)
was mixed in water (2.2 ml H2O/gram chow), soaked for 15 min,
and then mashed. Griseofulvin doses were prepared at 0.0% (con-
trol), 0.5%, and 1.0% with 0.0, 0.5, and 1.0 g griseofulvin : 10 ml
corn oil : 100 g mouse chow ratio, respectively. Both 0.5 and 1.0%
doses were expected to substantially inhibit FECH and induce a
protoporphyria-like phenotype, based on previously published work
(Lochhead et al, 1967; Holley et al, 1990; Martinez et al, 2009).
During treatment, the mice were examined and weighed 3 times/
week (Fig EV5A). On day 8, mice underwent L-CNV as above and
were imaged by OCT at day 15 and day 22, at which time they were
euthanized. The eyes were enucleated and flat mounts prepared as
described above. The livers were dissected out and weighed
(Fig EV5B).
NOS assay
NOS activity was measured in cells as described before (Ra¨thel et al,
2003). Briefly, HRECs (10,000 cells/well) were seeded in 96-well
clear-bottom black plates and incubated for 24 h at 37°C and 5%
CO2. Cells were washed with PBS and incubated for 5 min at 37°C
with 100 ll of 100 lM L-arginine prepared in PBS. Subsequently,
100 nM of DAF-2 diacetate was added to each well and fluorescence
readings were taken at excitation and emission wavelengths of 495
and 515 nm, respectively, using the Synergy plate reader (Biotek).
Hemin pull-down
HRECs were grown in EGM-2 medium in 10-cm plates until they
reached ~50% confluency. Cells were treated with 10 lM NMPP or
DMSO control for 1 week. Medium was changed every 2 days with
treatments added to the fresh medium every time. Cells were lysed
with NP-40 lysis buffer (20 mM Tris, pH 8.0, 150 mM NaCl, 1% NP-
40, 20 lM leupeptin, 1 mM PMSF, 1 mM NaF, 1 mM b-glyceropho-
sphate, 2 mM sodium orthovanadate, 2 mM EDTA, 10% glycerol)
and then centrifuged at 14,000 g for 10 min at 4°C. Supernatant was
collected and samples were pre-cleared by incubation with
Neutravidin beads for 1 h at 4°C followed by centrifugation at 500 g
for 5 min at 4°C. Supernatant was collected, and protein concentra-
tion was determined using a Bradford assay. Equal amounts of total
protein (40 lg) from each sample were incubated with ~50 ll hemin
agarose beads, pre-washed three times with lysis buffer, for 1 h at
4°C.
The beads were then washed two times in NP-40 buffer,
followed by two washes in high-salt buffer containing 20 mM
Tris–HCl pH 8.0, 350 mM NaCl, and 1 mM PMSF. The beads
were then washed once with a very high-salt buffer containing
20 mM Tris–HCl pH 8.0, 500 mM NaCl, and 1 mM PMSF. The
beads were then washed again in salt-free buffer containing
20 mM Tris–HCl and 1 mM PMSF. After 5-min incubation, the
beads were collected and any residual liquid was removed using
a Hamilton syringe. The hemin agarose beads were heated in
30 ll of 2× SDS–PAGE gel loading dye containing 30 ll of 2-
mercaptoethanol for 10 min at 70°C to release the bound proteins.
After heating, the contents were allowed to cool, and after a
quick spin, the eluate was collected using a Hamilton syringe.
Eluates were separated in a 4–20% gradient SDS–PAGE and then
transferred onto PVDF membranes. Proteins were immunoblotted
with antibodies against a-tubulin (1:1,000) or eNOS (1:500). All
dilutions were made in Tris-buffered saline–0.05% Tween-20
buffer containing 2% bovine serum albumin (BSA).
PPIX buildup assay
HRECs were grown in a 6-well plate until confluent. Cells were
serum starved overnight in EBM-2 medium. Fresh EGM-2 medium
containing DMSO or cremastranone (1) was added to cells, and they
were incubated at 37°C for 1 h followed by the addition of 1 mM
5-ALA to increase flux through the heme biosynthetic pathway. After
3 h of incubation in the dark at 37°C, the cells were trypsinized and
lysed in buffer containing 25 mM HEPES–NaOH pH 7.4, 150 mM
NaCl, 1% NP-40, 10% glycerol, and 1 mM PMSF. The cell lysates
were incubated in the dark at 4°C for 20 min on a shaker and centri-
fuged at 12,000 g for 15 min. Supernatants were collected for analy-
sis. In a 384-well black plate, 20 ll of supernatant was mixed with
20 ll of 1:1 solution of 2 M perchloric acid and methanol. After
5 min of incubation, fluorescence readings were taken at excitation
and emission wavelengths of 407 and 610 nm using the Synergy
plate reader.
Iron chelation
Compounds (cremastranone, EDTA, or deferoxamine) or DMSO
(1 ll) were incubated with 2.5 mM freshly prepared ferrous ammo-
nium sulfate in a final volume of 100 ll for 5 min at 37°C. Ferrozine
(100 ll of 2.5 mM solution) was added to the wells, and spec-
trophotometric readings were taken at 562 nm using the Synergy
plate reader. Decrease in absorbance readings at 562 nm repre-
sented the degree of iron chelation.
Apoptosis assays
The caspase-3 immunofluorescence assay was performed as
described previously (Basavarajappa et al, 2014). Briefly, cells were
plated on coated coverslips and incubated in EGM-2 medium over-
night before treating with siRNAs. After 24 h of transfection, the
cells were fixed in 4% paraformaldehyde and permeabilized using
0.5% Triton X-100 solution prepared in PBS. The cells were incu-
bated with cleaved caspase-3 antibody (1:200 dilution) overnight at
4°C. Dylight 488-conjugated goat anti-rabbit secondary antibody
(1:400) was used to probe the cleaved caspase-3 antibody. The
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coverslips were mounted using Vectashield mounting medium
containing DAPI for nuclear staining. The cells were imaged using
an LSM 700 confocal microscope.
The TUNEL assay was carried out as described previously
(Basavarajappa et al, 2015). Briefly, cells (25,000 per coverslip)
were seeded on coverslips and 24 h later the cells were transfected
with siRNAs or treated with the indicated compound concentrations
for 24 h. Cells were then fixed in 4% paraformaldehyde for 20 min
and permeabilized using 0.25% Triton X-100 prepared in PBS. Then,
apoptotic cells were visualized using the Click-iT TUNEL assay kit
as per the manufacturer’s instructions, with DAPI counter-stain. The
percentage of apoptotic cells was counted on three low-power fields
per coverslip using ImageJ software.
qRT–PCR
The assay was performed as described previously (Basavarajappa
et al, 2014). RNA was extracted from cells treated as indicated using
Trizol. cDNA was synthesized from 500 ng RNA using random
primers and iScript reverse transcriptase. qPCR was performed in
10 ll volumes in a 384-well plate, with Fast Advanced Master Mix
and TaqMan probes on a ViiA7 thermal cycler (Life Technologies).
Primer/probesets used were as follows: FECH (Hs01555261_m1),
HIF1A (Hs00153153_m1), NOS3 (Hs01574659_m1), VEGFA
(Hs00900055_m1), VEGFR2 (Hs00911700_m1), and housekeeping
controls GAPDH (Hs99999905_m1), HPRT (Hs02800695_m1), and
TBP (Hs00427620_m1). The data were analyzed using the DDCt
method (Livak & Schmittgen, 2001). The expression levels of genes
were normalized to the 3 housekeeping genes and calibrated to the
negative siRNA-treated sample.
Statistical analyses
Both in vitro and in vivo data were analyzed using unpaired
Student’s t-test or one-way ANOVA with Dunnett’s or Tukey’s post
hoc tests for comparisons between appropriate groups using
GraphPad Prism v. 7.0 software. The choroidal and retinal sprouting
assays were analyzed using two-way repeated measures ANOVA
with Dunnett’s post hoc tests, while the knockdown time course was
analyzed by two-way repeated measures ANOVA with Bonferroni’s
post hoc tests. Two-sided P-values < 0.05 were considered signifi-
cant in all tests.
Expanded View for this article is available online.
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